Sharer gets mediocre grade for Amgen tenure

Xconomy's Luke Timmerman assesses Amgen CEO Kevin Sharer's tenure this morning, giving him a gentleman's "C" for leadership, new product development, vision and other key factors. As Timmerman notes, C is the definition of mediocrity. His best grades come for leadership and vision, but there's an "F" for his rich salary and poor grades on industry relations and acquisitions. Column

Suggested Articles

Two weeks after receiving a second dose of Moderna's COVID-19 jab, patients had "robust" levels of neutralizing antibodies against the…

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.